A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (SUCCESSOR-1)
A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-1
- Relapsed or Refractory Multiple Myeloma
At a glance
- Phase
- Phase 3
- Study type
- Interventional
- Sponsor
- Celgene
- Enrolment target
- 810
- Started
- 20 September 2022
- Main results due (estimated)
- 10 January 2027
- Study ends (estimated)
- 30 November 2033
- Allocation
- Randomized
- Design
- Parallel
- Purpose
- Treatment
- Masking
- None
- Sites
- 266 · 8 in India
- First posted
- 29 August 2022
- Registry updated
- 30 October 2026
Can you take part?
- Aged 18 years and over.
- Open to any sex.
- You need the condition being studied. Healthy volunteers are not accepted.
Age groups: adult, older adult.
These are the headline rules. Every study has a longer list, and whether you are eligible is decided by the research team at the site, never by this page.
Read the full eligibility criteria
Inclusion Criteria \- Participant has documented diagnosis of MM and measurable disease, defined as any of the following:. i) M-protein ≥ 0.5 grams per deciliter (g/dL) by serum protein electrophoresis (sPEP) or. ii) M-protein ≥ 200 milligrams (mg) per 24-hour urine collection by urine protein electrophoresis (uPEP). iii) For participants without measurable disease in sPEP or uPEP: serum free light chain (sFLC) levels \> 100 mg/L (10 mg/dL) involved light chain and an abnormal kappa/lambda FLC ratio. * Participants received 1 to 3 prior lines of antimyeloma therapy. * Participants achieved minimal response \[MR\] or better to at least 1 prior antimyeloma therapy. Exclusion Criteria \- Participant has had progression during treatment or within 60 days of the last dose of a proteasome inhibitor, except as noted below:. i) Subjects who progressed while being treated with, or within 60 days of last dose of bortezomib maintenance given once every 2 weeks (or less frequently) are not excluded. ii) Participants who progressed while being treated with ixazomib monotherapy maintenance ≥ 6 months prior to the time of starting study treatment are not excluded. * For participants with prior treatment of a bortezomib containing regimen, the best response achieved was not a minimal response (MR) or better, or participant discontinued bortezomib due to toxicity. * Participant has had prior treatment with mezigdomide or pomalidomide. * Other protocol-defined Inclusion/Exclusion criteria apply.
What this study is about
In the sponsor’s own words, from the registry.
The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.
Keywords: Multiple myeloma · RRMM · MeziVd · PVd · CC92480 · pomalidomide · bortezomib · dexamethasone · mezigdomide
What participants receive
- Experimental
MeziVd (mezigdomide, bortezomib and dexamethasone)
Drug: mezigdomide · Drug: Bortezomib · Drug: Dexamethasone
- Experimental
PVd (pomalidomide, bortezomib and dexamethasone)
Drug: Pomalidomide · Drug: Bortezomib · Drug: Dexamethasone
Interventions
mezigdomideDrug
Also known as BMS-986348, CC-92480
Specified dose on specified days
PomalidomideDrug
Also known as Pomalyst, Imnovid, Pom
Specified dose on specified days
BortezomibDrug
Also known as Velcade, BTZ
Specified dose on specified days
DexamethasoneDrug
Also known as Decadron, Dex
Specified dose on specified days
What the study measures
Primary outcomes
Progression-free Survival (PFS)
Time frame: From date of randomization to date of disease progression or death due to any cause (Up to approximately 5 years)
Secondary outcomes
Recommended mezigdomide dose
Stage 1 only
Time frame: Up to 12 Months
Plasma concentrations of mezigdomide
Stage 1 only
Time frame: Up to 134 Days
Overall Survival (OS)
Time frame: From date of randomization to date of death due to any cause (Up to approximately 5 years)
Overall Response (OR)
OR is defined as the number of participants who achieve best response of partial response (PR) or better according to the International Myeloma Working Group (IMWG) Response Criteria for Multiple Myeloma
Time frame: Up to approximately 5 years
Complete Response (CR) or better
Defined as the number of participants who achieve best response of complete response (CR) or better according to the IMWG Uniform Response Criteria for Multiple Myeloma
Time frame: Up to approximately 5 Years
Very Good Partial Response (VGPR) or better
Defined as the number of participants who achieve best response of very good partial response (VGPR) or better according to the IMWG Uniform Response Criteria for Multiple Myeloma
Time frame: Up to approximately 5 years
Time to Response (TTR)
Time frame: Up to approximately 5 years
Duration of Response (DOR)
Time frame: Up to approximately 5 years
Time to Progression (TTP)
Time frame: Up to approximately 5 years
Time to Next Treatment (TTNT)
Time frame: Up to approximately 5 years
Progression-free Survival 2 (PFS-2)
Time frame: Up to approximately 5 years
Minimal Residual Disease (MRD) negativity
Defined as the number of participants who achieve complete response (CR) or better and MRD negativity (defined as less than 1 in 10\^5 nucleated cells \[by next generation flow cytometry\] in bone marrow aspirate)
Time frame: Up to approximately 5 years
Number of participants with Adverse Events (AEs)
Time frame: Up to approximately 5 years
Change from baseline in European Organization for Research and Treatment of Cancer - Quality of Life C30 questionnaire (EORTC QLQ-C30) scores
The EORTC QLQ-C30 is the most commonly used quality of life instrument in oncology trials. The QLQ-C30 consists of 30 questions incorporated into 5 functional domains physical, role, cognitive, emotional, and social), 9 symptom/other scales (fatigue, pain, nausea and vomiting, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties), and a single global Quality of Life (QoL)/global health status score. Items in the functional and symptom scale use raw participant response of 1 to 4, where 1 = "not at all" and 4 = "very much." The 2 global items contain responses ranging from 1 "very poor" to 7 "excellent." The recall period is 1 week. All domain scores are transformed in a range from 0 to 100, where a higher functional score indicates more favorable outcomes and a higher score on the symptom domains indicates a less favorable participant outcome. Stage 2 only.
Time frame: Up to approximately 5 years
Change from baseline in European Organization for Research and Treatment of Cancer - Quality of Life Multiple Myeloma Module (EORTC QLQ-MY20) score
The EORTC QLQ-MY20 is a 20-item myeloma module intended for use among participants varying in disease stage and treatment modality. Participants rate symptoms or problems on a scale from 1 to 4 where 1 = "not at all" and 4 = "very much." Stage 2 only.
Time frame: Up to approximately 5 years
Who is running it
- Lead sponsor
- Celgene
- Sponsor type
- Industry
- Responsible party
- The sponsor
- Organisation
- Celgene
- Data monitoring committee
- Yes
- US FDA-regulated drug
- Yes
- US FDA-regulated device
- No
- Sponsor's study ID
- CA057-001
- Other IDs
- 2023-509859-13, 2023
Bristol-Myers Squibb
Study director
Bristol-Myers Squibb
Study sites(266)
HCG Aastha Cancer Centre
Ahmedabad, Gujarat, India
Recruiting
- Abhishek Dudhatra, Site 03429978115559
Marengo Asia Hospitals Gurugram
Gurugram, Haryana, India
Recruiting
- Meet Kumar, Site 033809038791250
KLES Dr. Prabhakar Kore Hospital & M.R.C
Belagavi, Karnataka, India
Recruiting
- Rohan Bhise, Site 033609448866712
Mumbai Oncocare Centre - Nanachowk
Mumbai, Maharashtra, India
Recruiting
- Udip Maheshwari, Site 04167677434237
Christian Medical College & Hospital
Ludhiana, India
Recruiting
- M Joseph John, Site 03438054959525
Jawaharlal Institute Of Postgraduate Medical Education And Research
Puducherry, India
Recruiting
- Biswajit Dubashi, Site 03458056338305
Local Institution - 0344
Madurai, Tamil Nadu, India
Completed
Local Institution - 0341
Varanasi, Uttar Pradesh, India
Completed
TUM Klinikum
München, Bavaria, Germany
Recruiting
- Marion Hoegner, Site 0392498941405907
Klinikum Traunstein
Traunstein, Bavaria, Germany
Recruiting
- Matthias Egger, Site 039700498617052595
Medizinisches Versorgungszentrum
Weiden, Bavaria, Germany
Recruiting
- Thomas Schichtl, Site 0393+4930313660
Universitaetsklinik Marburg
Marburg, Hesse, Germany
Recruiting
- Christoph Mann, Site 0059064215861413
Praxis Onkologie am Raschplatz
Hanover, Lower Saxony, Germany
Recruiting
- Eyck von der Heyde, Site 04140177-6506614
Universitätsklinikum Bonn
Bonn, North Rhine-Westphalia, Germany
Recruiting
- Sebastian Schlaweck, Site 0092022828717000
Marien Hospital Düsseldorf
Düsseldorf, North Rhine-Westphalia, Germany
Recruiting
- Maika Klaiber-Hakimi, Site 0415021144006629
Universitaetsklinikum Schleswig-Holstein Campus Kiel
Kiel, Schleswig-Holstein, Germany
Recruiting
- Natalie Schub, Site 0058+49 431 500 22711
Universitätsklinikum Aachen
Aachen, Germany
Recruiting
- Deniz Gezer, Site 0391+49492418089770
Sozialstiftung Bamberg
Bamberg, Germany
Recruiting
- Christof Schweizer, Site 0390004995150313713
Gemeinschaftspraxis Hämatologie - Onkologie Freiberg-Richter, Jacobasch, Illmer, Wolf
Dresden, Germany
Recruiting
- Thomas Illmer, Site 041300493514400022
Universitaetsklinikum Hamburg-Eppendorf
Hamburg, Germany
Recruiting
- Katja Weisel, Site 00154940741058787
Asklepios Altona
Hamburg, Germany
Recruiting
- Hans-Jürgen Salwender, Site 038849-40-181881-1273
Universitaetsklinikum Tuebingen
Tübingen, Germany
Recruiting
- Britta Besemer, Site 00104970712982711
Gemeinschaftspraxis Dres. med. Björn Schöttker & Dominik Pretscher
Würzburg, Germany
Recruiting
- Dominik Pretscher, Site 03940049931322670
G. Papanikolaou General Hospital
Thessaloniki, Thessaloníki, Greece
Recruiting
- Ioanna Sakellari, Site 0189302313307550
Hospital de Braga
Braga, Portugal
Recruiting
Champalimaud Foundation
Lisbon, Portugal
Recruiting
Instituto Português de Oncologia do Porto Francisco Gentil, EPE
Porto, Portugal
Recruiting
- Angelo Martins, Site 0301351225084000
Pusan National University Hospital
Busan, Busan, South Korea
Recruiting
- Ho-Jin Shin, Site 0087821089371258
Seoul National University Bundang Hospital
Seongnam, Gyeonggido, South Korea
Recruiting
- Ji Yun Lee, Site 008682-10-6223-5401
Chonnam National University Hwasun Hospital
Hwasun, Jeonranamdo, South Korea
Recruiting
- Sung Hoon Jung, Site 008582613797623
Seoul National University Hospital
Seoul, Seoul Teugbyeolsi, South Korea
Recruiting
- Ja Min Byun, Site 0081821071243234
Samsung Medical Center
Seoul, Seoul Teugbyeolsi, South Korea
Recruiting
- Kihyun Kim, Site 0083+821099333456
The Catholic Univ. of Korea Seoul St. Mary's Hospital
Seoul, Seoul Teugbyeolsi, South Korea
Recruiting
- Chang Ki Min, Site 008482-20-2258-6053
Asan Medical Center
Seoul, Seoul-teukbyeolsi [Seoul], South Korea
Recruiting
- Dok Hyun Yoon, Site 025882230105940
Severance Hospital, Yonsei University Health System
Seoul, South Korea
Recruiting
- Jin Seok Kim, Site 009082222281972
Addenbrooke's Hospital
Cambridge, Cambridgeshire, United Kingdom
Recruiting
- Marquita Camilleri, Site 032644(0) 1223 596297
The Royal Cornwall Hospital
Truro, England, United Kingdom
Recruiting
- Adam Forbes, Site 021801872252765
King's College Hospital
London, Greater London, United Kingdom
Recruiting
- Kirsty Cuthill, Site 012844 (0) 20 3299 5501
Lanarkshire NHS Trust - Monklands Hospital
Airdrie, Lanarkshire, United Kingdom
Recruiting
- Iain Singer, Site 012701236 712754
Leicester Royal Infirmary
Leicester, Leicestershire, United Kingdom
Recruiting
- Shelina Sachedina, Site 013101162586617
Showing 40 of 266 sites. 42 recruiting, 200 not recruiting and 24 cancelled; 8 in India. Not recruiting covers sites not yet open, finished enrolling, completed or paused; cancelled covers sites withdrawn before opening or stopped for good.
References and data sharing
- Participant data shared
- Yes
- What is shared
- Study protocol, Sap, Csr
- When
- See Plan Description
- Access
- See Plan Description
BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Source: ClinicalTrials.gov record NCT05519085, status verified October 2026. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Interested in this study?
Tell us how to reach you and we will connect you with the study team. Or refer someone you care for, with their permission.